Serous chorioretinopathy—often called central serous chorioretinopathy (CSC)—happens when fluid seeps from a deeper layer of the eye and collects under the retina. This lifts the macula (the area responsible for fine, central vision) like a tiny blister, causing blurred or distorted vision, a central grey spot, shrunken-looking objects, or duller colours. It usually affects one eye at a time, often improves on its own over weeks to months, and can recur. While many people recover well, long‑standing or repeated episodes can leave lasting visual changes.
This guide explains who is most at risk, the common symptoms, causes and triggers, and how doctors diagnose CSC with scans and imaging. We outline acute versus chronic disease, treatment options such as observation, laser and photodynamic therapy, how to manage steroids safely, and practical lifestyle steps to reduce flare‑ups. You’ll also learn what recovery looks like, when to seek urgent care, how to monitor at home, and how CSC differs from macular degeneration.
Who gets serous chorioretinopathy?
Serous chorioretinopathy most often affects young to middle‑aged adults and is more common in men, particularly in their 30s to 50s. It typically involves one eye at a time, though both eyes can be affected. People under high stress or using corticosteroids are at higher risk, with links also seen to hypertension, pregnancy and sleep apnoea.
Symptoms of serous chorioretinopathy
Symptoms of serous chorioretinopathy usually affect the central vision and can start suddenly, typically in one eye. The severity depends on how much fluid collects and where it sits under the macula. Some people have few or no symptoms if the fluid is away from the macula, especially early on.
- Blurred or dim central vision
- Straight lines look bent or wavy (distortion)
- A dark or grey spot in the centre
- Objects appear smaller or further away (micropsia)
- Colours look washed out or duller, sometimes different between eyes
- Reduced detail for tasks like reading when the affected eye is used
Causes, triggers and risk factors
The cause of serous chorioretinopathy isn’t fully understood. It likely results from a leaky choroid with retinal pigment epithelium (RPE) dysfunction, letting fluid pool under the macula. Systemic corticosteroids can trigger or worsen episodes, and stress‑related cortisol may contribute. Several medical conditions and medicines raise risk.
- Corticosteroids in any form: tablets, injections, inhalers, creams, sprays.
- Stress/type A traits: psychological stress and elevated cortisol.
- Cardiovascular factors: high blood pressure or heart disease.
- Hormonal/sleep factors: obstructive sleep apnoea or sleep disturbance; pregnancy; Cushing syndrome.
- Certain medicines/family history: PDE‑5 inhibitors (ED drugs), decongestants, stimulants, some anti‑cancer agents; a family tendency.
How serous chorioretinopathy is diagnosed
Diagnosis begins with a comprehensive, dilated eye examination by an optometrist or ophthalmologist, who looks for a small, fluid‑related elevation of the macula and rules out other causes of macular swelling. Imaging confirms serous chorioretinopathy and provides a baseline to monitor recovery or recurrence over time.
- Optical coherence tomography (OCT): Quick, painless scans showing sub‑retinal fluid and RPE changes; enhanced depth OCT can assess the choroid.
- Fluorescein angiography: A dye test that highlights characteristic leakage patterns and helps distinguish CSC from other macular diseases.
- Indocyanine green angiography: Occasionally used to assess choroidal circulation and pinpoint leakage sites.
- Retinal photographs: Document appearance and track changes across visits.
Acute versus chronic serous chorioretinopathy
Doctors describe central serous chorioretinopathy as acute or chronic. Acute cases usually settle within one to four months as the fluid reabsorbs. Chronic disease means the fluid persists for several months or keeps returning, which can leave subtle, lasting changes (distortion, colour desaturation) and, rarely, a choroidal neovascular membrane. Because of this higher risk, chronic or recurrent CSC is more likely to need targeted treatment rather than observation alone.
Treatment options: observation, laser, photodynamic therapy and medicines
Most central serous chorioretinopathy (CSC) settles without intervention. Because serous chorioretinopathy often clears within one to four months, the first step is usually careful observation while addressing triggers such as corticosteroid use and stress. Treatment is considered if the fluid persists for several months, vision is significantly affected, the disease keeps recurring, or work and safety requirements demand quicker recovery.
- Observation and trigger control: Monitor with OCT while reducing modifiable risks (for example, reviewing steroid use with your doctor).
- Focal thermal laser: For a well‑defined leak away from the centre of the macula, laser photocoagulation can seal leakage and speed fluid clearance.
- Photodynamic therapy (PDT): A “cold laser” using verteporfin is effective in chronic or recurrent CSC, targeting the source of leakage and helping reduce recurrences.
- Medicines: In a small number of cases, an ophthalmologist may trial oral medication; this is individualised.
- Eye injections: If a rare complication called choroidal neovascular membrane develops, anti‑VEGF injections may be required.
Managing steroids and other medications safely
Because corticosteroids can trigger or worsen central serous chorioretinopathy, medication review is crucial. Never stop a steroid abruptly; speak with your GP or specialist about a safe taper or alternatives. Include all forms—tablets, inhalers, creams and sprays—and other drugs that might influence CSC.
- Bring a complete list, including OTC and supplements.
- Ask about steroid‑sparing options or lowest effective dose.
- Flag PDE‑5 inhibitors, decongestants, stimulants, anti‑cancer agents.
- Arrange OCT monitoring after any medication change.
Lifestyle changes that may reduce flare-ups
While you can’t prevent central serous chorioretinopathy outright, everyday habits can lower the chance of a flare‑up and support recovery. Prioritise reducing stress hormones, good‑quality sleep, and cardiovascular health. Work with your GP and ophthalmologist to address modifiable risks while your progress is tracked with OCT.
- Manage stress: mindfulness, regular exercise and structured downtime.
- Prioritise sleep/OSA care: consistent sleep; get assessed and treat sleep apnoea.
- Control blood pressure: keep readings in target range with your GP.
Recovery timeline, prognosis and recurrence
Most acute cases of serous chorioretinopathy recover as the eye reabsorbs fluid in 1–4 months, often sooner (weeks). Vision usually returns close to baseline, though slight distortion or colour dulling can linger. Treatment (laser or photodynamic therapy) is considered if fluid persists or vision is significantly affected and can speed resolution in selected cases. Recurrence is common: about half of people experience another episode, sometimes within 12 months. With prompt diagnosis and OCT monitoring, long‑term vision is typically preserved; chronic, persistent fluid carries higher risk.
Possible complications and long-term effects
Most people recover well, but central serous chorioretinopathy can leave subtle long‑term effects, especially when fluid persists or episodes repeat. The commonest are slight distortion and colour desaturation even after the fluid clears. Chronic or recurrent serous chorioretinopathy raises the risk of permanent macular changes and, rarely, a choroidal neovascular membrane needing treatment.
- Persistent mild central blur or distortion despite good acuity
- Subtle macular scarring/RPE changes on scans with reduced contrast or colour vibrancy
When to seek urgent eye care
Serous chorioretinopathy is usually painless, but sudden vision changes need prompt assessment. Seek same‑day care if your central vision worsens quickly, a new dark spot appears, or symptoms escalate—especially after starting corticosteroids. Early review helps confirm serous chorioretinopathy, rule out other causes, and protect your sight.
- Sudden drop in vision
- Rapidly worsening distortion
- A new central dark/grey spot
- Eye pain or marked redness
Monitoring your vision at home
Monitoring at home helps catch recurrences of serous chorioretinopathy (CSC) between appointments. An Amsler grid is a simple way to spot changes in central vision. Use it regularly and compare with previous notes; if you notice any sudden new blur, distortion or a dark patch, contact your eye health professional immediately.
- One eye at a time: note any distortion or missing areas on the grid.
- Record and review: keep dated photos/notes and follow your OCT monitoring plan.
How it differs from macular degeneration
It’s easy to confuse serous chorioretinopathy with age‑related macular degeneration, because both affect central vision. But they’re distinct conditions. Central serous chorioretinopathy (CSC) is usually a short‑lived, stress‑ and steroid‑linked fluid problem in younger people, while AMD is an age‑related, progressive macular disease needing long‑term care.
- Typical age: Serous chorioretinopathy affects young to middle‑aged adults (more men); AMD mainly affects older adults.
- Time course: CSC often resolves in 1–4 months; AMD tends to be ongoing and progressive.
- Mechanism: CSC is a serous fluid “blister” under the retina from RPE/choroidal leakage; AMD involves degenerative macular changes with risk of abnormal vessels.
- Management focus: CSC often starts with observation or targeted laser/PDT; AMD requires regular monitoring and tailored long‑term treatment.
If you’re unsure which condition you have, a dilated exam with OCT and, where needed, angiography will clarify the diagnosis and guide care.
How Bright Sight Eye Specialists cares for serous chorioretinopathy
At Bright Sight Eye Specialists in Randwick, Dr Rahul Dubey (Moorfields‑trained) provides streamlined care for serous chorioretinopathy. We confirm central serous chorioretinopathy with high‑resolution OCT and, when needed, fluorescein/ICG angiography, then tailor treatment: observation with OCT monitoring, steroid/trigger review with your GP, focal laser or photodynamic therapy for chronic cases, and anti‑VEGF injections if rare CNV develops. Coordinated, patient‑centred follow‑up is standard.
Key takeaways and next steps
CSC creates fluid under the macula that blurs and distorts central vision. Most episodes settle in 1–4 months; some recur or persist and benefit from targeted treatment. New central blur, distortion or a dark spot warrants prompt assessment. For tailored advice, OCT imaging and a clear plan, contact Bright Sight Eye Specialists.
- What it is: Sub‑retinal fluid lifting the macula.
- Who’s at risk: Men 30–50; stress; steroids; hypertension; pregnancy; sleep apnoea.
- Diagnosis: Dilated eye exam, OCT; angiography when needed.
- Treatment: Observe first; manage triggers; focal laser/PDT if persistent; anti‑VEGF for rare CNV.
- Outlook: Good recovery for most; up to half recur—monitor with Amsler and OCT.